HighTower Advisors LLC Makes New $65,000 Investment in Leap Therapeutics, Inc. (NASDAQ:LPTX)

HighTower Advisors LLC purchased a new stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 25,500 shares of the company’s stock, valued at approximately $65,000. HighTower Advisors LLC owned 0.10% of Leap Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of LPTX. Valence8 US LP bought a new position in Leap Therapeutics in the 3rd quarter valued at about $48,000. Marshall Wace LLP boosted its holdings in shares of Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after acquiring an additional 58,094 shares in the last quarter. Key Client Fiduciary Advisors LLC increased its stake in shares of Leap Therapeutics by 13.0% during the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock valued at $827,000 after acquiring an additional 37,067 shares during the period. Finally, Simplify Asset Management Inc. raised its holdings in Leap Therapeutics by 67.9% during the second quarter. Simplify Asset Management Inc. now owns 631,269 shares of the company’s stock worth $1,237,000 after purchasing an additional 255,293 shares in the last quarter. 30.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.50 price target on shares of Leap Therapeutics in a research note on Friday, November 15th.

Leap Therapeutics Price Performance

Shares of LPTX opened at $2.98 on Friday. The firm’s 50 day moving average is $3.11 and its 200-day moving average is $2.63. Leap Therapeutics, Inc. has a 12-month low of $1.68 and a 12-month high of $5.00. The stock has a market capitalization of $114.19 million, a P/E ratio of -1.54 and a beta of 0.21.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.